Earnings Call Summary | Helius Medical Technologies(HSDT.US) Q1 2024 Earnings Conference
Earnings Call Summary | Helius Medical Technologies(HSDT.US) Q1 2024 Earnings Conference
The following is a summary of the Helius Medical Technologies, Inc. (HSDT) Q1 2024 Earnings Call Transcript:
以下是Helius Medical Technologies, Inc.（HSDT）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Helius reported a Q1 2024 total revenue of $135,000, up from $111,000 in Q1 2023.
Cost of revenue remained similar to the previous year at $123,000.
Selling, general, and administrative expenses declined to $2.6 million mainly due to a decrease in professional fees and payroll-related overheads.
Research and development expenses decreased to $0.8 million as the company shifted focus to U.S. commercialization activities.
The operating loss was down to $3.4 million, with a net loss of $2.5 million.
Closed a $6.4 million public offering in May 2024 to extend the company's cash runway.
Helius報告稱，2024年第一季度的總收入爲13.5萬美元，高於2023年第一季度的11.1萬美元。
收入成本與上年相似，爲12.3萬美元。
銷售、一般和管理費用下降至260萬美元，這主要是由於專業費用和與工資相關的管理費用減少。
由於公司將重點轉移到美國的商業化活動上，研發費用降至80萬美元。
營業虧損降至340萬美元，淨虧損250萬美元。
2024 年 5 月完成了 640 萬澳元的公開募股，以延長公司的現金流。
Business Progress:
業務進展：
Focus on securing widespread reimbursement for PoNS and achieving FDA approval for stroke.
CMS established HCPCS codes for the PoNS, facilitating negotiations with third-party payers.
Partnering with Global Government Services to widen accessibility to PoNS within federal healthcare systems.
Establishing sites in five separate Canadian regions to validate PoNS therapy for stroke patients.
Anticipating a positive impact on revenues and cash flow from the final determination of payment rates, effective October 1, 2024.
專注於確保PON的廣泛報銷，並獲得美國食品藥品管理局對中風的批准。
CMS爲PON制定了HCPCS代碼，促進了與第三方付款人的談判。
與全球政府服務部門合作，擴大聯邦醫療系統內PON的可及性。
在加拿大五個不同的地區建立站點，以驗證中風患者的PoNs療法。
預計最終確定付款率將對收入和現金流產生積極影響，自2024年10月1日起生效。
More details: Helius Medical Technologies IR
更多詳情： Helius 醫療科技 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。